CN102357171A - Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof Download PDFInfo
- Publication number
- CN102357171A CN102357171A CN2011103301079A CN201110330107A CN102357171A CN 102357171 A CN102357171 A CN 102357171A CN 2011103301079 A CN2011103301079 A CN 2011103301079A CN 201110330107 A CN201110330107 A CN 201110330107A CN 102357171 A CN102357171 A CN 102357171A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- traditional chinese
- hepatic fibrosis
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and a preparation method and application thereof. The composition is prepared by taking traditional Chinese medicines, namely angelica, red flower, peach kernel, the root bark of the peony tree, root of common peony, Ligusticum wallichii, the root of three-nerved spicebush, trogopterus dung, corydalis tuber, rhizoma cyperi, fructus aurantii and liquorice, as raw materials according to the weight ratio of 9:9:9:6:6:6:6:9:3:5:5:9. The preparation method of the composition comprises the following steps of: taking the traditional Chinese medicines according to the ratio; decocting by using water for two times, each time for 1 h at the beginning of boiling, wherein the volume of water for the first time is 10 times as much as the total weight of the traditional Chinese medicines; and the volume of water for the second time is 8 times as much as the total weight of the traditional Chinese medicines; and finally, mixing the two kinds of decoction liquid and concentrating. The traditional Chinese medicine composition disclosed by the invention is capable of reducing serum transaminase, lightening liver collagen precipitation degree and improving hepatic inflammatory and fibrosis pathological change, has the function of preventing and curing hepatic fibrosis pathological change, and can be applied to preparing a pharmaceutical preparation for preventing and curing hepatic fibrosis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of preventing and treating hepatic fibrosis, belong to technical field of Chinese medicines.
Background technology
Hepatic fibrosis is meant diffusivity extracellular matrix hyperplasia and abnormal deposition in the liver.Hepatic fibrosis is not an independently disease, but the common pathological process of many chronic hepatopathys.Almost various chronic hepatic diseases comprise that chronic type b (third type) viral hepatitis, chronic schistosomiasis, chronic ethanol and drug induced injury, autoimmune liver disease etc. all have this chronic pathology and change.The hepatic fibrosis sustainable development can further cause liver cirrhosis even hepatocarcinoma, has a strong impact on patient health and life.Therefore slow down, stop and reverse the critical treatment strategy that hepatic fibrosis is a chronic hepatopathy.Yet still there is not the fibrosis Western medicine that gets the Green Light so far clinically.Therefore, press for and develop anti-hepatic fibrosis medicines safely and effectively.
The long-term clinical practice accumulation of Chinese medicine prevention chronic hepatopathy has been established solid foundation for the Chinese medicine research of anti-hepatic fibrosis.Though do not see the name of disease of hepatic fibrosis in the TCM Document; But according to its symptom and sign; This disease belongs to categories such as Chinese medicine " hypochondriac pain ", " gathering ", " mass in the abdomen ", " tympanites "; obstruction of collaterals by blood stasis, liver-spleen disharmony are its main pathogenic characteristics, and the blood circulation promoting and blood stasis dispelling circulation of qi promoting is the basic rule of treatment of the traditional Chinese medical science of hepatic fibrosis.Therefore the compound recipe that meets the basic rule of treatment of the hepatic fibrosis traditional Chinese medical science is furtherd investigate, had wide development and application prospect.
Summary of the invention
One of the object of the invention provides a kind of Chinese medicine composition that can effectively prevent and treat hepatic fibrosis; Two of the object of the invention provides the preparation method and its usage of the Chinese medicine composition of above-mentioned control hepatic fibrosis.
A kind of Chinese medicine composition of preventing and treating hepatic fibrosis provided by the invention; Be to be raw material, according to weight ratio 9: 9: 9: 6: 6: 6: 6: 9: 3: be prepared from 5: 5: 9 by Chinese crude drug Radix Angelicae Sinensis, Flos Carthami, Semen Persicae, Cortex Moutan, Radix Paeoniae Rubra, Rhizoma Chuanxiong, the Radix Linderae, Oletum Trogopterori, Rhizoma Corydalis, Rhizoma Cyperi, Fructus Aurantii, Radix Glycyrrhizae.
A kind of method for preparing of preventing and treating the Chinese medicine composition of hepatic fibrosis provided by the invention; Be to get Chinese crude drug at first in proportion, water decocted 2 times then, from each 1 hour of boiling timing; For the first time the water volume is 10 times of medical material gross weight; For the second time the water volume is 8 times of medical material gross weight, merges decoction liquor at last twice, concentrates to be prepared from.
Chinese medicine composition of the present invention or described Chinese medicine composition and pharmaceutically acceptable pharmaceutical carrier can be applicable to prepare the pharmaceutical preparation that prevents and treats hepatic fibrosis.
Described pharmaceutical preparation can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch; The preferred oral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Described peroral dosage form can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.Suitable filler comprises cellulose, mannitol, lactose and other similar filler; Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate; Suitable lubricant comprises, for example magnesium stearate; The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Chinese medicine composition of the present invention is made up of Radix Angelicae Sinensis, Flos Carthami, Semen Persicae, Cortex Moutan, Radix Paeoniae Rubra, Rhizoma Chuanxiong, the Radix Linderae, Oletum Trogopterori, Rhizoma Corydalis, Rhizoma Cyperi, Fructus Aurantii, Radix Glycyrrhizae.Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Rubra nourshing blood and promoting blood circulation in the side, with the same usefulness of medicine for expelling stasis, blood stasis dispelling and non-impairment of YIN; The gas of Rhizoma Chuanxiong in more can promoting the circulation of blood wherein strengthens the power of removing blood stasis; The Cortex Moutan clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling; Semen Persicae, Flos Carthami, Oletum Trogopterori removing blood stasis are with the removing food stagnancy piece; Compatibility Rhizoma Cyperi, the Radix Linderae, Fructus Aurantii, Rhizoma Corydalis promoting the circulation of QI to relieve pain; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.Full side is in the majority with blood circulation and removing stasis and circulation of qi promoting medicine, makes gas general blood capable, better brings into play its blood circulation and removing stasis, the disappear power of knot of broken disease.Full side's effect blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain are coincide with the basic rule of treatment of the traditional Chinese medical science of hepatic fibrosis.This prescription medicine function blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, the pathogenesis of the hepatic fibrosis of hitting.
The present invention adopts carbon tetrachloride (carbon tetrachloride, the CCl of extensive use
4) inductive hepatic fibrosis in mice model and N-nitrosodimethylamine (Dimethylnitrosamine; DMN) inductive rat liver fibrosis model, use respectively Chinese medicine composition low (mice 5.5g crude drug/kg, rat 3.5g crude drug/kg), in (11g crude drug/kg; Rat 7g crude drug/kg), high (22g crude drug/kg; Rat 14g crude drug/kg) dose groups prophylactic and medicine for treatment, the result shows that Chinese medicine composition of the present invention is to Liver Fibrosis Model rat and mice; But transaminase lowering, alleviate liver collagen deposition degree, improve liver inflammatory and fibrosis pathology and change, have the effect of prevention and treatment hepatic fibrosis pathological changes.
Description of drawings
Fig. 1 is that Chinese medicine composition of the present invention is to CCl
4The influence of the serum aminotransferase activity of Liver Fibrosis Model mice.
Fig. 2 is that Chinese medicine composition of the present invention is to CCl
4The influence of the hepatic tissue hydroxyproline content of Liver Fibrosis Model mice.
Fig. 3 is that Chinese medicine composition of the present invention is to CCl
4The influence that the hepatic pathology of Liver Fibrosis Model mice changes.
Fig. 4 is that Chinese medicine composition of the present invention is to CCl
4The influence of the liver collagen deposition of Liver Fibrosis Model mice.
Fig. 5 is the influence of Chinese medicine composition of the present invention to the serum aminotransferase activity of DMN Liver Fibrosis Model rat.
Fig. 6 is the influence of Chinese medicine composition of the present invention to the hepatic tissue hydroxyproline content of DMN Liver Fibrosis Model rat.
Fig. 7 is the influence of Chinese medicine composition of the present invention to the hepatic pathology variation of DMN Liver Fibrosis Model rat.
Fig. 8 is the influence of Chinese medicine composition of the present invention to the liver collagen deposition of DMN Liver Fibrosis Model rat.
Among the figure: N-representes normal group; M-representation model matched group; Low-expression mice is pressed 5.5g crude drug/kg dosage, and rat is pressed 3.5g crude drug/kg dosage; In-expression mice press 11g crude drug/kg dosage, rat is pressed 7g crude drug/kg dosage; Height-expression mice is pressed 22g crude drug/kg dosage, and rat is pressed 14g crude drug/kg dosage; P-representes positive controls, and mice is pressed 0.15g/kg dosage and uses N-acetyl-L-cysteine, and rat is used perindopril by 5mg/kg dosage.
The specific embodiment
Below in conjunction with specific embodiment and accompanying drawing, further set forth the present invention.These embodiment are interpreted as only being used to explain the present invention rather than being used to limit protection scope of the present invention.After the content of having read the present invention's record, those skilled in the art can do various changes or modification to the present invention, and these equivalences change and modify and fall into claims of the present invention institute restricted portion equally.
Used Radix Angelicae Sinensis, Flos Carthami, Semen Persicae, Cortex Moutan, Radix Paeoniae Rubra, Rhizoma Chuanxiong, the Radix Linderae, Oletum Trogopterori, Rhizoma Corydalis, Rhizoma Cyperi, Fructus Aurantii, Radix Glycyrrhizae all meets the relevant each item regulation under each medical material item of text of Chinese Pharmacopoeia version in 2010 in the embodiment of the invention.Each medical material has passed through processed such as clean system, cutting, the process of preparing Chinese medicine, pulverizing, before feeding intake, is tested and appraised, and each medical material material object of distinguishing the flavor of conforms to title, and quality meets NF standard (concrete medical material evaluation way is carried out with reference to standards of pharmacopoeia).
Embodiment 1
Get Chinese crude drug Radix Angelicae Sinensis 900 grams, Flos Carthami 900 grams, Semen Persicae 900 grams, Cortex Moutan 600 grams, Radix Paeoniae Rubra 600 grams; Rhizoma Chuanxiong 600 grams, the Radix Linderae 600 grams, Oletum Trogopterori 900 grams, Rhizoma Corydalis 300 grams, Rhizoma Cyperi 500 grams; Fructus Aurantii 500 grams, Radix Glycyrrhizae 900 grams, decocting boiled 2 times, from each 1 hour of boiling timing; Water 82L for the first time, water 65.6L merges decoction liquor twice, simmer down to 3000mL for the second time.
Test Example 1 (anti-CCl
4The hepatic fibrosis mouse experiment)
Select male C57BL/6 mice in 10 ages in week for use, the cleaning level is supplied with by Shanghai Slac Experimental Animal Co., Ltd..Mice is divided into normal group (N), model group (M), basic, normal, high dose groups and positive drug group (P) at random.Except that normal group (lumbar injection equivalent normal saline), all the other each groups are all with 10%CCl
4Olive oil solution 2ml/kg mice body weight lumbar injection is injected continuous 4 weeks weekly 3 times.From modeling; Basic, normal, high dose groups gives Chinese medicine composition 5.5g of the present invention, 11g, 22g crude drug/kg body weight extractum filling stomach respectively; The positive drug group gives N-acetyl-L-cysteine 0.15g/kg body weight and irritates stomach, and in totally 4 weeks, normal group and model group wait the capacity normal saline.Medication finishes the back and measures mice serum glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT activity and hepatic tissue hydroxyprolin levels, carries out hepatic tissue pathology dyeing and the inspection of Sirius red colouring.
Result of the test shows: the middle and high dose groups prophylactic of Chinese medicine composition of the present invention can reduce the mice serum gpt activity, and high dose group can reduce the active (see figure 1) of glutamic oxaloacetic transaminase, GOT, among the figure
*P＜0.05,
*P＜0.01vs model.Chinese medicine composition high dose group of the present invention also can reduce murine liver tissue hydroxyproline content (see figure 2).Hepatic tissue HE coloration result shows, the visible extensive degeneration necrosis of hepatocyte of model group, portal area massive inflammatory cells infiltrated, the obvious hypertrophy of fibroblast; The middle and high dose groups hepatocellular degeneration of Chinese medicine composition necrosis alleviates, and inflammatory cell infiltration and fibroblast proliferation obviously reduce (see figure 3); Hepatic tissue Sirius is red collagen staining result show, the visible more pseudolobuli in model group portal area forms, a large amount of collagen fiber depositions; The middle and high dose groups of Chinese medicine composition does not see that obvious pseudolobuli forms, and the collagen fiber deposition alleviates (see figure 4).
This Test Example shows that Chinese medicine composition of the present invention has preventive effect to the hepatic fibrosis pathological changes.
Test Example 2 (anti-DMN rat liver fibrosis experiment)
Select male Wistar rat for use, cleaning level, body weight 150-180g.Supply with by Shanghai Slac Experimental Animal Co., Ltd..Rat is divided into normal group (N) and model group at random, and model group is with DMN 10 μ l/kg body weight dosage lumbar injections, and every day 1 time, weekly for three days on end, in totally 4 weeks, wherein the 1st week injection 2/3 is measured.Normal group lumbar injection equivalent normal saline; After 4 weeks of animal via becoming mould; Rat model be divided at random model group (M), Chinese medicine composition low (3.5g crude drug/kg body weight), in (7g crude drug/kg body weight), high (14g crude drug/kg body weight) dose groups and positive drug control group (P) (perindopril 5mg/kg body weight), model group waits the capacity normal saline.Each medication group filling stomach is totally 4 weeks.Medication finishes the back and measures rat blood serum glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT and hepatic tissue hydroxyprolin levels, carries out hepatic tissue pathology dyeing, the inspection of Sirius red colouring.
Result of the test shows: traditional Chinese medicine composition for treating medication of the present invention can reduce rat blood serum glutamate pyruvate transaminase and the active (see figure 5) of glutamic oxaloacetic transaminase, GOT.The middle and high dose groups of Chinese medicine composition of the present invention also can reduce liver tissues of rats hydroxyproline content (see figure 6), among the figure
*P＜0.05,
*P＜0.01vs model.Hepatic tissue HE coloration result shows, the visible extensive degeneration necrosis of hepatocyte of model group, the more inflammatory cell infiltration in portal area, the obvious hypertrophy of fibroblast; Middle and high dose groups hepatocellular degeneration of Chinese medicine composition and necrosis alleviate, and inflammatory cell infiltration and fibroblast proliferation obviously reduce (see figure 7); Hepatic tissue Sirius is red collagen staining result show, the visible more pseudolobuli in model group portal area forms, and see a large amount of collagen fiber depositions; The middle and high dose groups of Chinese medicine composition does not see that pseudolobuli forms, and the collagen fiber deposition is obviously improved (see figure 8).
This Test Example shows that Chinese medicine composition of the present invention has therapeutical effect to the hepatic fibrosis pathological changes.
Claims (3)
1. Chinese medicine composition of preventing and treating hepatic fibrosis; It is characterized in that; By Chinese crude drug Radix Angelicae Sinensis, Flos Carthami, Semen Persicae, Cortex Moutan, Radix Paeoniae Rubra, Rhizoma Chuanxiong, the Radix Linderae, Oletum Trogopterori, Rhizoma Corydalis, Rhizoma Cyperi, Fructus Aurantii, Radix Glycyrrhizae is raw material, according to weight ratio 9: 9: 9: 6: 6: 6: 6: 9: 3: be prepared from 5: 5: 9.
2. the method for preparing of the Chinese medicine composition of the described control hepatic fibrosis of claim 1; It is characterized in that: get Chinese crude drug at first in proportion, water decocted 2 times then, from each 1 hour of boiling timing; For the first time the water volume is 10 times of medical material gross weight; For the second time the water volume is 8 times of medical material gross weight, merges decoction liquor at last twice, concentrates to be prepared from.
3. described Chinese medicine composition of claim 1 or described Chinese medicine composition and the pharmaceutically acceptable pharmaceutical carrier application in the pharmaceutical preparation of preparation control hepatic fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103301079A CN102357171A (en) | 2011-10-26 | 2011-10-26 | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103301079A CN102357171A (en) | 2011-10-26 | 2011-10-26 | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102357171A true CN102357171A (en) | 2012-02-22 |
Family
ID=45582588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103301079A Pending CN102357171A (en) | 2011-10-26 | 2011-10-26 | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102357171A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798806A (en) * | 2017-03-18 | 2017-06-06 | 佛山市弘泰药物研发有限公司 | A kind of Chinese patent drug and its preparation technology for chronic hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506098A (en) * | 2002-12-10 | 2004-06-23 | 姚希贤 | Medicine composition for treating liver fibrillation and liver cirrhosis and its prepn process |
-
2011
- 2011-10-26 CN CN2011103301079A patent/CN102357171A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506098A (en) * | 2002-12-10 | 2004-06-23 | 姚希贤 | Medicine composition for treating liver fibrillation and liver cirrhosis and its prepn process |
Non-Patent Citations (2)
| Title |
|---|
| "中医药治疗肝纤维化研究近况", 《江苏中医药》, 31 August 2004 (2004-08-31) * |
| 张洁玉: "膈下逐瘀汤抗肝纤维化的作用机制及配伍实验研究", 《黑龙江中医药大学博士学位论文》, 31 December 2004 (2004-12-31), pages 40 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798806A (en) * | 2017-03-18 | 2017-06-06 | 佛山市弘泰药物研发有限公司 | A kind of Chinese patent drug and its preparation technology for chronic hepatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN102512632B (en) | Chinese herbal composition for treating abnormal menstruation | |
| CN101708297A (en) | Medicament for treating gout disease | |
| CN105125851A (en) | Traditional Chinese medicine treating 2-type diabetes and preparation technology | |
| CN103316305B (en) | Traditional Chinese medicine composition for treating liver cirrhosis and preparation method thereof | |
| CN103768542A (en) | Medicine for treating ascites due to liver cancer and preparation method thereof | |
| CN103623292A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102302544B (en) | Chinese medicinal composition for preventing and treating hepatic fibrosis | |
| CN102357171A (en) | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN104189781A (en) | Pharmaceutical composition for treating neuroglioma | |
| CN103638389A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103656524A (en) | Traditional Chinese medicine composition for treating liver cirrhosis | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN102423468B (en) | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof | |
| CN103041320B (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites | |
| CN101088555B (en) | Medicine preparation for inhibiting tumor angiogenesis and cancer cell and enhancing immunity | |
| CN104547927A (en) | Medicine for treating child anorexia and preparation method of medicine | |
| CN103948875A (en) | Medicine for treating hepatitis B and preparation method thereof | |
| CN1175875C (en) | Medicine made of lysimachia for treating hepatobiliary calculus and its prescription | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN103816493B (en) | A kind of Chinese medicine composition treating instability of kidney QI | |
| CN101780188B (en) | Capsule for treating prostatic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120222 |